Physician profile
Christopher Manley
NPI 1992936330
$261,693.38
in general payments reported to CMS, 2019-2025
18 companies · $40K in 2025
The $40K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $27K · 2021: $24K · 2022: $36K · 2023: $29K · 2024: $49K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $98K · Travel and Lodging: $15K · Food and Beverage: $4,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $98,292.26 |
| Travel and Lodging | $15,250.28 |
| Food and Beverage | $4,177.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $178,327.80 | 2019-2025 | Monarch Platform, N/A |
| Medical Device Business Services, INC. | $61,436.83 | 2019-2025 | Monarch Platform, Monarch |
| Auris Health, INC. | $9,737.19 | 2019 | |
| Janssen Scientific Affairs, LLC | $6,060.00 | 2021 | |
| Boston Scientific Corporation | $3,586.17 | 2019-2024 | |
| Noah Medical Corporation | $917.50 | 2023-2024 | Galaxy |
| Ethicon Endo-Surgery INC. | $904.42 | 2023 | Monarch Platform |
| Daiichi Sankyo INC. | $146.60 | 2022-2025 | Vanflyta, Injectafer, Enhertu |
| Astrazeneca Pharmaceuticals Lp | $111.75 | 2019 | |
| Pulmonx Corporation | $102.21 | 2019 | |
| Galvanize Therapeutics, INC | $92.94 | 2023-2025 | Aliya System |
| Intuitive Surgical, INC. | $87.66 | 2023-2024 | Da Vinci Surgical System |
| Mauna Kea Technologies, INC. | $54.85 | 2023 | |
| Fujifilm Healthcare Americas Corporation | $41.48 | 2025 | |
| Covidien Lp | $39.60 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $28.56 | 2025 | Erleada |
| Glaxosmithkline, LLC. | $17.82 | 2025 | Nucala |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Manley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.